Loading
Karyopharm Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Sept 2023.
Karyopharm Therapeutics Inc.: what insiders have been doing
This page follows insider dealings at Karyopharm Therapeutics Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 28 filings came from 8 insiders.
All open-market trades in the period are sales: 14 sales worth €271k, by 7 insiders, with no purchase on record. One trade stands out by size: a sale of €99k from Paulson Richard A., disclosed on 3 March 2026.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 28 filings here. Since 2021, the database holds 3 purchases and 105 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 146.1 m USD and net income at -196.0 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
178
Thresholds
n/a
Buy Volume
€238,115
3 ops. · all time
Sell Volume
€4M
105 ops. · all time
Who traded when
BuySaleKristin Abate9 sales
Richard A. Paulson8 sales
Stuart Poulton6 sales
Reshma Rangwala4 sales
Sohanya Roshan Cheng3 sales
Michael Mano2 sales
+1 other insider
Since the insiders bought
- -42.5%Entry US$19.20 · Close at T+365 US$11.04
- -41.9%Entry US$132.60 · Close at T+365 US$77.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.51
Analyst consensus
4 analysts1.80/5
US$3.00Target US$7.25(+1336%)US$11.00
Income statement
RevenueUS$146.1M
Gross profitUS$140.1M96% margin
EBITDA-US$149.9M-103% margin
Net income-US$196M-153.3% margin
Valuation
PER (forward)-0.2x
Beta1.04
Balance sheet & cash
Market capUS$11.5M
Total debtUS$233.6M
Free Cash Flow-US$75.4M
Profitability & ownership
ROA-47.6%
% insiders4.7%
% institutions95.9%
Last declaration on 2 October 2026
Declarations178 total
378 shares@ US$1.190.0016% mcap3.0% of flowCommon StockSEC:0001193125-26-412209:0
189 shares@ US$7.100.0034% mcap1.0% of flowCommon StockSEC:0001193125-26-326290:0
15,508 shares0Common StockSEC:0001254705-26-000008:0
324 shares@ US$9.500.0068% mcap2.6% of flowCommon StockSEC:0001193125-26-226652:1
53 shares@ US$9.500.0011% mcap3.4% of flowCommon StockSEC:0001193125-26-226616:1
700 shares0Common StockSEC:0001193125-26-226604:0
896 shares0Common StockSEC:0001193125-26-226697:0
121 shares0Common StockSEC:0001193125-26-226616:0
947 shares0Common StockSEC:0001193125-26-226652:0
4,920 shares0Common StockSEC:0001193125-26-226613:0
947 shares0Common StockSEC:0001193125-26-226685:0
449 shares@ US$8.940.0088% mcap3.7% of flowCommon StockSEC:0001825322-26-000006:0
5,101 shares@ US$9.409534.3% of flowCommon StockSEC:0001942597-26-000003:0
4,604 shares@ US$9.409536.6% of flowCommon StockSEC:0001865796-26-000003:0
12,361 shares@ US$9.409520.2% of flowCommon StockSEC:0001804460-26-000003:0
559 shares@ US$9.409535.4% of flowCommon StockSEC:0002045943-26-000003:0
3,526 shares@ US$9.409539.9% of flowCommon StockSEC:0001837741-26-000003:0
5,066 shares@ US$9.409543.8% of flowCommon StockSEC:0001825322-26-000003:0
378 shares@ US$8.632.3% of flowCommon StockSEC:0001193125-26-059332:0
81,060 shares0Common StockSEC:0001193125-26-042799:0
1,626 shares@ US$6.30100.0% of flowCommon StockSEC:0001193125-26-037584:0
32,415 shares0Common StockSEC:0001193125-26-035682:0
32,415 shares0Common StockSEC:0001193125-26-035663:0
32,415 shares0Common StockSEC:0001193125-26-035655:0
32,415 shares0Common StockSEC:0001193125-26-035687:0
25 of 178 declarations
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq (United States) and headquartered in Newton, Massachusetts. Founded in 2008, the company built its scientific identity around inhibition of nuclear export, a differentiated mechanism intended to disrupt the survival and proliferation of cancer cells. Karyopharm is now a commercial-stage organization with an international footprint that includes presence in Germany and Israel, while its operational center remains in the United States. ([karyopharm.com](https://www.karyopharm.com/about/company-overview/?utm_source=openai))
The company’s business is anchored by XPOVIO® (selinexor), its flagship oral oncology therapy. XPOVIO is FDA-approved in multiple hematologic cancer settings, including multiple myeloma, and remains Karyopharm’s principal commercial asset and revenue driver. Beyond this marketed product, the company is advancing a clinical pipeline focused on high-unmet-need oncology indications, with several drug candidates in development. Karyopharm states that it has one approved product and multiple clinical-stage programs, underscoring a model that combines commercial execution with late-stage pipeline optionality. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-refractory-or-relapsed-multiple-myeloma?utm_source=openai))
Read moreShow less
From a competitive standpoint, Karyopharm operates in highly contested oncology markets alongside larger pharmaceutical companies and specialized biotech peers. Its edge lies in its XPO1 biology and in a focused strategy targeting difficult-to-treat cancers where treatment options remain limited. That niche orientation can be attractive if clinical data translate into meaningful efficacy and tolerability advantages, but it also leaves the company exposed to regulatory risk, competitive pressure, and the financing needs typical of small-cap biotech names. ([karyopharm.com](https://www.karyopharm.com/about/?utm_source=openai))
Recent developments are especially important for the investment case. In late 2025 and early 2026, Karyopharm highlighted that top-line data from its Phase 3 SENTRY trial in myelofibrosis were expected in March 2026, while top-line results from a Phase 3 endometrial cancer study were still on track for mid-2026. The company also reported that 2025 revenue was driven largely by U.S. XPOVIO net product sales and discussed cost-reduction actions, liquidity management, and recent financing activity. For French-speaking investors, Karyopharm should be viewed as a Nasdaq-listed U.S. oncology company with a concentrated commercial base, a clinically driven near-term catalyst calendar, and meaningful upside or downside sensitivity to 2026 trial readouts. ([investors.karyopharm.com](https://investors.karyopharm.com/2026-02-12-Karyopharm-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlights-Recent-Company-Progress?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
